IL10 and melanoma: On the other hand, our studies indicate that therapeutic treatment of mice with the TLR4/9 agonist complex after inoculation of B16F10 melanoma cells can not reverses tumor cell-induced STAT3 activation, IL-10 expression, and autophagy suppression in the lung tissues.